Pulse Biosciences (PLSE) has released an update.
Pulse Biosciences, Inc. recently announced the achievement of a milestone in their innovative medical technology, with the successful remapping of the first four patients using their CellFX® nsPFA™ 360° Cardiac Catheter in a First-In-Human Feasibility Study. This development could pique the interest of investors watching for advancements in the medical device sector.
For further insights into PLSE stock, check out TipRanks’ Stock Analysis page.
